DTU Logo
Publications | Conference abstracts | Slidesets | Webcasts

Publications (27 of 430)

Search Publications :


Exenatide Case Report
Price HC, Holman RR
International Diabetes 2009;15:15. Published:24-Jan-2011
[Full text]

Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes
Bernard Zinman, Steven M. Haffner, William H. Herman, Rury R. Holman, John M. Lachin, Barbara G. Kravitz, Gitanjali Paul, Nigel P. Jones, R. Paul Aftring, Giancarlo Viberti, Steven E. Kahn, and the A Diabetes Outcome Progression Trial Study Group
J Clin Endocrinol Metab 2009;95:134-142. Published:Jan-2010. Epub:29-Oct-2009. PMID:19875477. doi:10.1210/jc.2009-0572

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
David M. Nathan, John B. Buse, Mayer B. Davidson, Ele Ferrannini, Rury R. Holman, Robert Sherwin, Bernard Zinman
Clinical Diabetes 2009;27:4-16. Published:21-Dec-2009. doi:10.2337/diaclin.27.1.4

Metabolic syndrome and alanine aminotransferase: a global perspective from the NAVIGATOR screening population
M. A. Bethel, P. Deedwania, N. S. Levitt, O. Schmitz, A. Huntsman-Labed, R. M. Califf, S. M. Haffner and P. Diem for the NAVIGATOR Study Groupp
Diabetic Medicine 2009;26:1204-1211. Published:Dec-2009. Epub:30-Sep-2009. PMID:20002471. doi:10.1111/j.1464-5491.2009.02864.x

Perceptions of heart attack risk amongst individuals with diabetes
Hermione C Price, Christina Dudley, Beryl Barrow, Simon J Griffin & Rury R Holman
Primary Care Diabetes 2009;3:239 -244. Published:Nov-2009. Epub:05-Nov-2009. PMID:19896425. doi:10.1016/j.pcd.2009.09.005

Intensive glucose control and macrovascular outcomes in type 2 diabetes
F. M. Turnbull, C. Abraira, R. J. Anderson, R. P. Byington, J. P. Chalmers, W. C. Duckworth, G. W. Evans, H. C. Gerstein, R. R. Holman, T. E. Moritz, B. C. Neal, T. Ninomiya, A. A. Patel, S. K. Paul, F. Travert and M. Woodward
Diabetologia 2009;52:2288-2298. Published:Nov-2009. Epub:05-Aug-2009. PMID:19655124. doi:10.1007/s00125-009-1470-0

Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes
Rury R. Holman, Andrew J. Farmer, Melanie J. Davies, Jonathan C. Levy, Julie L. Darbyshire, Joanne F. Keenan, and Sanjoy K. Paul for the 4-T Study Group
N Eng J Med 2009;361:1736-47. Published:29-Oct-2009. Epub:22-Oct-2009. PMID:19850703. doi:10.1056/NEJMoa0905479

Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses
Lasserson DS, Glasziou P, Perera R, Holman RR, Farmer AJ
Diabetologia 2009;52:1990-2000. Published:Oct-2009. Epub:31-Jul-2009. PMID:19644668. doi:10.1007/s00125-009-1468-7

Use of focus groups to develop methods to communicate cardiovascular disease risk and potential for risk reduction to people with type 2 diabetes
Price HC, Dudley C, Barrow B, Kennedy IA, Griffin SJ, Holman RR
Family Practice 2009;26:351-358. Published:Oct-2009. Epub:21-Jun-2009. PMID:19546119. doi:10.1093/fampra/cmp041

Presenting the results of clinical trials to participants
Julie L Darbyshire, Rury R Holman and Hermione C Price
Clin Med 2009;9:415-416. Published:Oct-2009. PMID:19886097. doi:10.7861/clinmedicine.9-5-415

Cardiovascular disease risk estimation: Why, when and how?
Price HC
Diabetes and Primary Care 2009;11:218-223. Published:Aug-2009
[Full text]

International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes
Nathan DM, Balkau B, Bonora E, Borch-Johnsen K, Buse JB, Colagiuri S, Davidson MB, DeFronzo R, Genuth S, Holman R, Linong Ji, Kirkman S, Knowler WC, Schatz D, Shaw J, Sobngwi E, Steffes M, Vaccaro O, Wareham N, Zinman B, Kahn R
Diabetes Care 2009;32:1327-1334. Published:Jul-2009. Epub:05-Jun-2009. PMID:19502545. doi:10.2337/dc09-9033

Limitations of Existing Diabetes Treatment
Holman RR
Novo Nordisk Annual Report 2009;30. Published:24-Jun-2009

Follow-up of Intensive Glucose Control in Type 2 Diabetes - Authors' reply
Holman RR, Matthews DM, Neil HAW
N Eng J Med 2009;360:418. Published:24-Jun-2009. PMID:19164195. doi:10.1056/NEJMc082275

Predicting 6-year mortality risk in patients with type 2 diabetes: response to Wells et al.
Paul S, Coleman RL, Price HC, Farmer AJ
Diabetes Care 2009;32:e60. Published:May-2009. PMID:19407070. doi:10.2337/dc09-0183

European physicians overestimate life expectancy and the likely impact of interventions in individuals with Type 2 diabetes
Price HC, Thorne KI , Dukat A, Kellett J
Diabetic Medicine 2009;26:453-455. Published:Apr-2009. Epub:27-Feb-2009. PMID:19388980. doi:10.1111/j.1464-5491.2009.02702.x

Performance of the UKPDS Risk Engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort
Simmons RK, Coleman RL, Price HC, Holman RR, Khaw K, Wareham NJ, Griffin SJ
Diabetes Care 2009;32:708-713. Published:Apr-2009. Epub:29-Dec-2008. PMID:19114615. doi:10.2337/dc08-1918

Primary prevention of cardiovascular events in diabetes: is there a role for aspirin?
Price HC, Holman RR
Nature Clinical Practice Cardiovasc Medicine 2009;6:168-169. Published:Mar-2009. Epub:20-Jan-2009. PMID:19153560. doi:10.1038/ncpcardio1446

Impact of using a non-diabetes-specific risk calculator on eligibility for statin therapy in type 2 diabetes
Price HC, Coleman RL, Stevens RJ, Holman RR
Diabetologia 2009;52:394-397. Published:Mar-2009. Epub:02-Dec-2008. PMID:19048226. doi:10.1007/s00125-008-1231-5

Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial
Farmer AJ, Wade AN, French DP, Simon J, Yudkin P, Gray A, Craven A, Goyder L, Holman RR, Mant D, Kinmonth A-L and Neil HAW, on behalf of the DiGEM Trial Group
Health Technology Assessment 2009;13:1-71. Published:Mar-2009. PMID:19254484. doi:10.3310/hta13150

Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes
Hartweg J, Farmer AJ, Holman RR, Neil A
Curr Opin Lipidol 2009;20:30-38. Published:Feb-2009. PMID:19133409. doi:10.1097/MOL.0b013e328321b3be

Community Cardiology Clinics for Secondary Prevention of Coronary Heart Disease and Heart Failure in Primary Care
Khunti K, MD, Stone M, Paul S, Squire I.
Cardiology Review 2009;25:64-67. Published:05-Jan-2009
[Full text]

Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial
Holman RR, Paul S, Farmer A, Tucker L, Stratton IM, Neil HA on behalf of the AFORRD study group
Diabetologia 2009;52:50 - 59. Published:Jan-2009. Epub:11-Nov-2008. PMID:19002433. doi:10.1007/s00125-008-1179-5

Prevalence of Glucokinase (GCK) Mutations in Individuals Screened for Fasting Hyperglycaemia
Gloyn AL, van de Bunt M, Stratton IM, Lonie L, Tucker L, Ellard S, Holman RR
Diabetologia 2009;52:172-174. Published:Jan-2009. Epub:11-Nov-2008. PMID:19002431. doi:10.1007/s00125-008-1188-4

Medical Management of Hyperglycemia in Type 2 Diabetes: a Consensus Algorithm for the Initiation and Adjustment of Therapy
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B
Diabetes Care 2009;32:193-203. Published:Jan-2009. Epub:22-Oct-2008. PMID:18945920. doi:10.2337/dc08-9025

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B
Diabetologia 2009;52:17-30. Published:Jan-2009. Epub:22-Oct-2008. PMID:18941734. doi:10.1007/s00125-008-1157-y

Changing diabetes by improving control: Outcome trials
Holman RR
Journal of Diabetes Nursing 2009;13:39. Published:Jan-2009